ArticleFundamental research2024
Large-scale heterogeneous synthesis of monodisperse high performance colloidal CsPbBr
Article in Fundamental research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colloidal lead halide perovskite nanocrystals (LHP NCs) are promising semiconductor materials for optoelectronic devices, but the high ionicity of LHP NCs makes their crystallization control and post-treatment difficult. Here, phosphonic acids (PAs) are employed as ligands to design a solid-liquid heterogeneous reaction system to regulate the LHP NC crystallization and achieve the desired focusing growth. During the heterogeneous synthesis, the precursors in the liquid phase are responsible for the burst nucleation and initial growth of NCs. Afterwards, the focusing growth of NCs is supported by the precursors released from the solid phase. In addition, the strong binding ability of PAs enables effective passivation of LHP NCs. Without post-treatment, gram-scale monodisperse CsPbBr
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.